Skip to main content
SpringerLink
Log in

Bispecific and Biparatopic Antibody Drug Conjugates

  • Chapter
  • First Online:
Innovations for Next-Generation Antibody-Drug Conjugates

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

The conceptual framework for antibody drug conjugates (ADC’s) emerged contemporaneously with the discovery of antibodies, with Paul Ehrlich proposing in the early 1900’s the concept of a “magic bullet”, an ideal therapeutic that would specifically target a disease-causing agent without causing harm to the body. This concept still underpins the overarching goal of biopharmaceutical development today: to produce drugs that have a broad therapeutic index by effectively targeting the disease while causing minimal damage to normal tissue. Although the concept of ADC’s is simple, achieving the ideal combination of properties has proven challenging, as reflected by the limited number of ADC’s that have demonstrated success in the clinic to date. Recent years have witnessed a burgeoning field, with the number of clinical stage ADC’s more than doubling in just the last two years to more than 70 candidates currently in clinical development. Despite the successes to date and the prospect of new ADC’s reaching patients in the coming years, many challenges remain and there is substantial room for improvement, most notably in improving the therapeutic index. The key challenge in developing an ADC is balancing its efficacy and safety. This review will focus on ways to capitalize on bispecific antibody technology to improve the therapeutic index of ADC’s, in pursuit of the magic bullet ideal. The nature of bispecific antibodies allows for fine tuning of the interactions between each target to impact the overall properties of the molecule. Here, we discuss some of the cutting edge bispecific antibody strategies that are currently under investigation to address both the efficacy and safety aspects of ADC’s.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Beck A et al (2017) Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov 16:315

    Article  CAS  PubMed  Google Scholar 

  2. Thomas A, Teicher BA, Hassan R (2016) Antibody–drug conjugates for cancer therapy. Lancet Oncol 17(6):e254-e262

    Article  CAS  PubMed  Google Scholar 

  3. Lambert JM, Morris CQ (2017) Antibody-drug conjugates (ADCs) for personalized treatment of solid tumors: a review. Adv Ther 34:1015

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Tolcher AW (2016) Antibody drug conjugates: lessons from 20 years of clinical experience. Ann Oncol 27(12):2168–2172

    Article  CAS  PubMed  Google Scholar 

  5. Kontermann RE (2012) Dual targeting strategies with bispecific antibodies. MAbs 4(2):182–197

    Article  PubMed  PubMed Central  Google Scholar 

  6. May C, Sapra P, Gerber H-P (2012) Advances in bispecific biotherapeutics for the treatment of cancer. Biochem Pharmacol 84(9):1105–1112

    Article  CAS  PubMed  Google Scholar 

  7. Yang F, Wen W, Qin W (2016) Bispecific antibodies as a development platform for new concepts and treatment strategies. Int J Mol Sci 18(1)

    Article  CAS  PubMed Central  Google Scholar 

  8. Fan GW et al (2015) Bispecific antibodies and their applications. J Hematol Oncol:8

    Google Scholar 

  9. Boku N (2014) HER2-positive gastric cancer. Gastric Cancer 17(1):1–12

    Article  CAS  PubMed  Google Scholar 

  10. ZW33, Anti-HER2 x HER2 ADC Overview, Zymeworks Company Website. July 2017.; Available from: https://www.zymeworks.com/our-pipeline/zw33

  11. Li JY et al (2016) A Biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer Cell 29(1):117–129

    Article  CAS  PubMed  Google Scholar 

  12. Mazor Y et al (2017) Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence. Sci Rep 7:40098

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. de Goeij BE et al (2016) Efficient payload delivery by a bispecific antibody-drug conjugate targeting HER2 and CD63. Mol Cancer Ther 15(11):2688–2697

    Article  PubMed  Google Scholar 

  14. Andreev J et al (2017) Bispecific antibodies and antibody-drug conjugates (ADCs) bridging HER2 and prolactin receptor improve efficacy of HER2 ADCs. Mol Cancer Ther 16:681

    Article  CAS  PubMed  Google Scholar 

  15. Nisonoff A, Rivers MM (1961) Recombination of a mixture of univalent antibody fragments of different specificity. Arch Biochem Biophys 93(2):460

    Article  CAS  PubMed  Google Scholar 

  16. Brennan M, Davison PF, Paulus H (1985) Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science 229(4708):81–83

    Article  CAS  PubMed  Google Scholar 

  17. Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517):495–497

    Article  CAS  PubMed  Google Scholar 

  18. Brinkmann U, Kontermann RE (2017) The making of bispecific antibodies. MAbs 9(2):182–212

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Spiess C, Zhai Q, Carter PJ (2015) Alternative molecular formats and therapeutic applications for bispecific antibodies. Therapeutic antibodies: discovery, design and deployment. Mol Immunol 67(2, Part A):95–106

    Article  CAS  PubMed  Google Scholar 

  20. Ha JH, Kim JE, Kim YS (2016) Immunoglobulin Fc heterodimer platform technology: from design to applications in therapeutic antibodies and proteins. Front Immunol 7:394

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Liu H et al (2017) Fc engineering for developing therapeutic bispecific antibodies and novel scaffolds. Front Immunol 8:38

    PubMed  PubMed Central  Google Scholar 

  22. Krah S et al (2017) Engineering bispecific antibodies with defined chain pairing. New Biotechnol 39:167

    Article  CAS  Google Scholar 

  23. Bostrom J et al (2009) Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323(5921):1610–1614

    Article  CAS  PubMed  Google Scholar 

  24. Fischer N et al (2015) Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG. Nat Commun 6:6113

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Dimasi N et al (2017) Guiding bispecific monovalent antibody formation through proteolysis of IgG1 single-chain. MAbs 9(3):438–454

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Choi HJ et al (2015) Engineering of immunoglobulin fc heterodimers using yeast surface-displayed combinatorial fc library screening. PLoS One 10(12):e0145349

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Wranik BJ et al (2012) LUZ-Y, a novel platform for the mammalian cell production of full-length IgG-bispecific antibodies. J Biol Chem 287(52):43331–43339

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Leaver-Fay A et al (2016) Computationally designed bispecific antibodies using negative state repertoires. Structure 24(4):641–651

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Moretti P et al (2013) BEAT® the bispecific challenge: a novel and efficient platform for the expression of bispecific IgGs. BMC Proc 7(6):O9

    Article  PubMed Central  Google Scholar 

  30. Davis JH et al (2010) SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng Des Sel 23(4):195–202

    Article  CAS  PubMed  Google Scholar 

  31. de Kruif C.A., Hendriks L.J.A., Logtenberg T. (2016) Methods and means for the production of Ig-like molecules. Google Patents

    Google Scholar 

  32. Choi HJ et al (2013) A heterodimeric Fc-based bispecific antibody simultaneously targeting VEGFR-2 and met exhibits potent antitumor activity. Mol Cancer Ther 12(12):2748–2759

    Article  CAS  PubMed  Google Scholar 

  33. Strop P et al (2012) Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. J Mol Biol 420(3):204–219

    Article  CAS  PubMed  Google Scholar 

  34. Gunasekaran K et al (2010) Enhancing antibody fc heterodimer formation through electrostatic steering effects applications to bispecific molecules and monovalent IgG. J Biol Chem 285(25):19637–19646

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Von Kreudenstein TS et al (2013) Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design. MAbs 5(5):646–654

    Article  Google Scholar 

  36. Merchant AM et al (1998) An efficient route to human bispecific IgG. Nat Biotechnol 16(7):677–681

    Article  CAS  PubMed  Google Scholar 

  37. Labrijn AF et al (2013) Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci 110(13):5145–5150

    Article  PubMed  Google Scholar 

  38. Moore GL et al (2011) A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. MAbs 3(6):546–557

    Article  PubMed  PubMed Central  Google Scholar 

  39. Schaefer W et al (2011) Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A 108(27):11187–11192

    Article  PubMed  PubMed Central  Google Scholar 

  40. Mazor Y et al (2015) Improving target cell specificity using a novel monovalent bispecific IgG design. MAbs 7(2):377–389

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Liu Z et al (2015) A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism. J Biol Chem 290(12):7535–7562

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Coloma MJ, Morrison SL (1997) Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol 15(2):159–163

    Article  CAS  PubMed  Google Scholar 

  43. DiGiandomenico A et al (2014) A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med 6(262):262ra155

    Article  CAS  PubMed  Google Scholar 

  44. Bezabeh B et al (2017) Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties. MAbs 9(2):240–256

    Article  CAS  PubMed  Google Scholar 

  45. Hinrichs MJ, Dixit R (2015) Antibody drug conjugates: nonclinical safety considerations. AAPS J 17(5):1055–1064

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Donaghy H (2016) Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs 8(4):659–671

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Mazor Y et al (2015) Insights into the molecular basis of a bispecific antibody's target selectivity. MAbs 7(3):461–469

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Jakob CG et al (2013) Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig (TM)) molecule. MAbs 5(3):358–363

    Article  PubMed  PubMed Central  Google Scholar 

  49. Godar M et al (2016) Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy. Sci Rep 6

    Google Scholar 

  50. Ritchie M, Tchistiakova L, Scott N (2013) Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. MAbs 5(1):13–21

    Article  PubMed  PubMed Central  Google Scholar 

  51. Xu S (2015) Internalization, trafficking, intracellular processing and actions of antibody-drug conjugates. Pharm Res 32(11):3577–3583

    Article  CAS  PubMed  Google Scholar 

  52. Austin CD et al (2004) Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 15(12):5268–5282

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Robert B et al (1999) Tumor targeting with newly designed biparatopic antibodies directed against two different epitopes of the carcinoembryonic antigen (CEA). Int J Cancer 81(2):285–291

    Article  CAS  PubMed  Google Scholar 

  54. Friedman LM et al (2005) Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci U S A 102(6):1915–1920

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Spangler JB et al (2010) Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc Natl Acad Sci U S A 107(30):13252–13257

    Article  PubMed  PubMed Central  Google Scholar 

  56. Hackel BJ et al (2012) Epidermal growth factor receptor downregulation by small heterodimeric binding proteins. Protein Eng Des Sel 25(2):47–57

    Article  CAS  PubMed  Google Scholar 

  57. Dienstmann R et al (2015) Safety and activity of the first-in-class Sym004 anti-EGFR antibody mixture in patients with refractory colorectal cancer. Cancer Discov 5(6):598–609

    Article  CAS  PubMed  Google Scholar 

  58. Pedersen MW et al (2010) Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 70(2):588–597

    Article  CAS  PubMed  Google Scholar 

  59. Brack S et al (2014) A bispecific HER2-targeting FynomAb with superior antitumor activity and novel mode of action. Mol Cancer Ther 13(8):2030–2039

    Article  CAS  PubMed  Google Scholar 

  60. Thuss-Patience PC et al (2017) Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol 18:640

    Article  CAS  PubMed  Google Scholar 

  61. Perez EA et al (2017) Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE study. J Clin Oncol 35(2):141–148

    Article  CAS  PubMed  Google Scholar 

  62. Burstein HJ (2005) The distinctive nature of HER2-positive breast cancers. N Engl J Med 353(16):1652–1654

    Article  CAS  PubMed  Google Scholar 

  63. Lee JM et al (2016) Novel strategy for a bispecific antibody: induction of dual target internalization and degradation. Oncogene 35:4437

    Article  CAS  PubMed  Google Scholar 

  64. Pols MS, Klumperman J (2009) Trafficking and function of the tetraspanin CD63. Exp Cell Res 315(9):1584–1592

    Article  CAS  PubMed  Google Scholar 

  65. Waldron NN et al (2014) A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma. Target Oncol 9(3):239–249

    Article  PubMed  Google Scholar 

  66. Tzeng A et al (2015) Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution. Proc Natl Acad Sci 112(11):3320–3325

    Article  CAS  PubMed  Google Scholar 

  67. Sellmann C et al (2016) Balancing selectivity and efficacy of bispecific EGFR x c-MET antibodies and antibody-drug conjugates. J Biol Chem 291:25106

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Rudnick SI, Adams GP (2009) Affinity and avidity in antibody-based tumor targeting. Cancer Biother Radiopharm 24(2):155–161

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Kovtun YV, Goldmacher VS (2007) Cell killing by antibody-drug conjugates. Cancer Lett 255(2):232–240

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Biosuperiors, MedImmune LLC, Gaithersburg, MD, USA

    Frank Comer

  2. Antibody Discovery and Protein Engineering, MedImmune LLC, Gaithersburg, MD, USA

    Changshou Gao

  3. Oncology Development, MedImmune LLC, Gaithersburg, MD, USA

    Steve Coats

Authors
  1. Frank Comer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Changshou Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Steve Coats
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frank Comer .

Editor information

Editors and Affiliations

  1. Mersana Therapeutics, Inc., Cambridge, Massachusetts, USA

    Marc Damelin

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Comer, F., Gao, C., Coats, S. (2018). Bispecific and Biparatopic Antibody Drug Conjugates. In: Damelin, M. (eds) Innovations for Next-Generation Antibody-Drug Conjugates. Cancer Drug Discovery and Development. Humana Press, Cham. https://doi.org/10.1007/978-3-319-78154-9_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-78154-9_11

  • Published:

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-78153-2

  • Online ISBN: 978-3-319-78154-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation